arXiv:2608. 06961v1 Announce Type: new Abstract: Early-stage molecular design is an iterative process, not just a task of generating molecules.
By Zhu Wang, Jiangyu Chen, Yingjun Shang, Yuhui Yao, Laiao Lu, Tianfan Fu, Na Zou
arXiv:2610.23791v1 Announce Type: new
Abstract: Computational drug discovery requires agents to compose scientific operations and adapt to changing evidence and constraints. Here we introduce DrugHar...
By Yuxing Chen, Zhisheng Zhang, Cheng Tang, Wei Li, Minghui Zhang, Ziyan Huang, Shaocong Wei, Jiawei Chen, Junru Hu, Hongze Zhu, Jianghan Shen, Min Cen, Xinyuan Zhu, Yaxue Zhao, Jubo Wang, Yuqiang Li, Chun-Mei Feng, Zongyuan Ge, Rui Su, Jie Xu, Yirong Chen, Xi Xu, Ming Hu
arXiv:2502. 18864v2 Announce Type: replace Abstract: Scientific discovery is driven by scientists generating novel hypotheses for complex problems that undergo rigorous experimental validation.
By Juraj Gottweis, Wei-Hung Weng, Alexander Daryin, Tao Tu, Petar Sirkovic, Artiom Myaskovsky, Grzegorz Glowaty, Felix Weissenberger, Alessio Orlandi, Dan Popovici, Anil Palepu, Keran Rong, Ryutaro Tanno, Khaled Saab, Fan Zhang, Jacob Blum, Andrew Carroll, Kavita Kulkarni, Nenad Tomasev, Dina Zverinski, Ivor Rendulic, Elahe Vedadi, Florian Hasler, Luka Rimanic, Marina Boia, Ivan Budiselic, Ben Feinstein, Mathias Bellaiche, Tom Sheffer, Jan Freyberg, Jeremy Ratcliff, Ottavia Bertolli, Katherine Chou, Avinatan Hassidim, Burak Gokturk, Amin Vahdat, Yuan Guan, Vikram Dhillon, Eeshit Dhaval Vaishnav, Byron Lee, Tiago R D Costa, Jos\'e R Penad\'es, Gary Peltz, Yossi Matias, James Manyika, Demis Hassabis, Yunhan Xu, Pushmeet Kohli, Annalisa Pawlosky, Alan Karthikesalingam, Vivek Natarajan
arXiv:2610.16975v1 Announce Type: new
Abstract: Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to...
By Ye Liu, Reza Averly, Avery Meyer, Frazier N. Baker, Ruoxi Gao, Daniel Adu-Ampratwum, Xia Ning
arXiv:2608. 02642v1 Announce Type: cross Abstract: Accelerating scientific discovery is among the most consequential applications of AI, and computational biomolecular simulation stands out as a particularly promising target within this broader effort.
By Nithishwer Mouroug Anand, Wei-Tse Hsu, Kyle Vaccaro, Eden James Gage, Jonathan David Colburn, Linda Xi Phan, Minjoon Seo, Kevin Guan, Philip C. Biggin
The paper introduces MAGI, an open modular agent that orchestrates molecular‑design tools by setting objectives, launching optimization, interpreting structure–activity relationships, and adjusting strategy. In nine retrospective lead‑optimization campaigns from three pharmaceutical companies, MAGI produced valid molecules via either direct LLM generation or delegation to REINVENT 4; LLM proposals stayed closer to local chemistry and achieved comparable or higher activity with fewer operations, while REINVENT explored broader chemical space. The success of a campaign depended on the accuracy of predictive models rather than the generation route, and a blinded evaluation showed chemists could not distinguish MAGI’s outputs from expert‑generated compounds, though the SAR reasoning was deemed plausible yet incomplete. The study positions MAGI as a coordination layer that can be plugged into existing workflows, but notes that the current ceiling for real projects is set by scorer applicability rather than tool orchestration.
By Pierre Llompart, Levent Guner, Helen Lai, Alessandro Tibo, Yijie Xu